Management of Infections in Patients with Indwelling Catheters

Initial Assessment and Treatment

• Patients with suspected infections should immediately receive intravenous empiric antibiotic therapy with an anti-pseudomonal β-lactam agent, and obtain at least 2 sets of blood cultures, urine culture, complete blood count, serum creatinine, and liver function tests before initiating antibiotics, as recommended by the Infectious Diseases Society of America 1
• Consider vancomycin if there is suspicion of catheter-related infection, which is likely in patients with indwelling catheters, as suggested by the American College of Clinical Pharmacology 1
• For patients with concern for intra-abdominal or pelvic source, consider adding metronidazole to the treatment regimen 2
• Severe neutropenia (ANC <0.5 × 10^9/L) requires immediate empirical antibiotic therapy within 1 hour of presentation, along with granulocyte colony-stimulating factor (G-CSF) administration in high-risk patients, as recommended by the European Society for Medical Oncology and supported by the Clinical Infectious Diseases guidelines and the Infectious Diseases Society of America 3, 1, 3

Ongoing Management and Monitoring

• Daily assessment of fever trends, clinical status, and laboratory parameters is crucial in managing patients with infections 2
• Evaluate for subtle signs of infection at common sites, such as the periodontium, pharynx, lower esophagus, lung, perineum, and skin 4
• Consider catheter removal or exchange if clinical condition does not improve within 48-72 hours 2
• Obtain blood cultures and cultures from suspected sites of infection, and perform a chest radiograph for patients with respiratory symptoms or if outpatient management is planned, as recommended by the Clinical Infectious Diseases guidelines and the Infectious Diseases Society of America, with a strength of evidence level of high 1, 3, 4

Antibiotic Duration and Discontinuation

• The Infectious Diseases Society of America recommends treating documented urinary tract infection with an indwelling catheter for 7-10 days 1
• Continue broad-spectrum antibiotics until the patient has been afebrile for at least 2 days AND the neutrophil count is >500 cells/mm³, based on the principle that antibiotics are required to contain occult infection during neutropenia, but adequate effector cells are necessary for patient protection 1
• High-risk patients (expected prolonged neutropenia >7 days) should continue initial antibiotic regimen until there are clear signs of marrow recovery (ANC >500 cells/mm³) 1
• Low-risk patients who are afebrile after 3 days of IV therapy can consider step-down to oral antibiotics (ciprofloxacin plus amoxicillin-clavulanate) 1
• The ECIL-4 guidelines recommend consideration of discontinuation of antibiotics after 72 hours in clinically stable patients without proven infection who have been afebrile for 48 hours, regardless of neutrophil count, suggesting a potential for shorter antibiotic courses in selected patients 5

Antibiotic Selection

• Monotherapy with Cefepime, meropenem, imipenem/cilastatin, or piperacillin/tazobactam is recommended for febrile neutropenia, with a strength of evidence level of high, as recommended by the European Society for Medical Oncology 3
• Combination therapy with an aminoglycoside should be considered in severe sepsis, as recommended by the European Society for Medical Oncology, with a strength of evidence level of moderate 3
• Vancomycin should be added if there is suspected catheter-related infection, known colonization with MRSA, hemodynamic instability, pneumonia, or soft-tissue infection, according to the Clinical Infectious Diseases guidelines, with a strength of evidence level of high 1, 4

Neutropenia Management

• The following table summarizes the definition of neutropenia:

4

• Primary prophylaxis with G-CSF is recommended when the risk of febrile neutropenia is >20%, and secondary prophylaxis with G-CSF is indicated after a previous episode of febrile neutropenia, according to the Infectious Diseases Society of America and other guidelines, with a strength of evidence level of high 6
• Consider antibacterial prophylaxis with fluoroquinolones (levofloxacin preferred) for high-risk patients with expected prolonged neutropenia (ANC <100 cells/mm³ for >7 days), according to the Clinical Infectious Diseases guidelines and the Infectious Diseases Society of America, with a strength of evidence level of high 1, 3, 7, 8

Infection Prevention

• Infection prophylaxis should be considered in high-risk patients with end-stage lymphoma to prevent infections and their associated complications, according to the National Comprehensive Cancer Network, with a strength of evidence level of moderate 9
• Using prophylactic antibiotics without a clear indication can lead to the development of resistance, according to various guidelines, with a strength of evidence level of high 10
• Overlooking fungal infections can lead to poor outcomes, and consideration of empirical antifungal therapy is recommended in patients with persistent fever after 4-7 days of antibiotics, as suggested by the Clinical Infectious Diseases guidelines and the Infectious Diseases Society of America, with a strength of evidence level of moderate 3, 4, 7